Cardiac troponin and heart failure in the era of high-sensitivity assays

Journal of Cardiology

Volumn 60, Issue 3, 2012, Pages 160-167

  Sato, Yukihito ^a   Fujiwara, Hisayoshi ^a   Takatsu, Yoshiki ^a  

^a Hyogo Prefectural Amagasaki Hospital   (Japan)

Author keywords

Heart failure; Hypertension; Natriuretic peptide; Troponin

Indexed keywords

ANTINEOPLASTIC AGENT; BRAIN NATRIURETIC PEPTIDE; TROPONIN C; TROPONIN I; TROPONIN T;

ACUTE HEART FAILURE; ASSAY; CANCER CHEMOTHERAPY; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); HEART AMYLOIDOSIS; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; MYOCARDIAL DISEASE; MYOCARDITIS; NONHUMAN; PROGNOSIS; PROTEIN SECRETION; REVIEW; RISK FACTOR;

AMYLOIDOSIS; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; CARDIOMYOPATHY, HYPERTROPHIC; HEART FAILURE; HUMANS; MYOCARDITIS; RISK; TROPONIN;

EID: 84866153431     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.06.007     Document Type: Review

References (100)

1. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008, 358:2148-2159.
2. Anand I.S., Florea V.G., Fisher L. Surrogate end points in heart failure. J Am Coll Cardiol 2002, 39:1414-1421.
3. Tang W.H., Francis G.S., Morrow D.A., Newby L.K., Cannon C.P., Jesse R.L., Storrow A.B., Christenson R.H., Apple F.S., Ravkilde J., Wu A.H., National Academy of Clinical Biochemistry Laboratory Medicine National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation 2007, 116:e99-e109.
4. Thygesen K., Alpert J.S., White H.D., Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Jaffe A.S., Apple F.S., Galvani M., Katus H.A., Newby L.K., Ravkilde J., Chaitman B., Clemmensen P.M., Dellborg M., Hod H., Porela P., et al. Universal definition of myocardial infarction. Circulation 2007, 116:2634-2653.
5. Jeremias A., Gibson C.M. Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med 2005, 142:786-791.
6. Babuin L., Jaffe A.S. Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ 2005, 173:1191-1202.
7. Korff S., Katus H.A., Giannitsis E. Differential diagnosis of elevated troponins. Heart 2006, 92:987-993.
8. Agewall S., Giannitsis E., Jernberg T., Katus H. Troponin elevation in coronary vs. non-coronary disease. Eur Heart J 2011, 32:404-411.
9. Kelley W.E., Januzzi J.L., Christenson R.H. Increases of cardiac troponin in conditions other than acute coronary syndrome and heart failure. Clin Chem 2009, 55:2098-2112.
10. Jaffe A.S., Wu A.H. Troponin release-reversible or irreversible injury? Should we care?. Clin Chem 2012, 58:148-150.
11. Gaze D.C., Collinson P.O. Multiple molecular forms of circulating cardiac troponin: analytical and clinical significance. Ann Clin Biochem 2008, 45:349-355.
12. Giannitsis E., Kurz K., Hallermayer K., Jarausch J., Jaffe A.S., Katus H.A. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem 2010, 56:254-261.
13. Apple F.S., Smith S.W., Pearce L.A., Ler R., Murakami M.M. Use of the Centaur TnI-Ultra assay for detection of myocardial infarction and adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem 2008, 54:723-728.
14. Reichlin T., Hochholzer W., Bassetti S., Steuer S., Stelzig C., Hartwiger S., Biedert S., Schaub N., Buerge C., Potocki M., Noveanu M., Breidthardt T., Twerenbold R., Winkler K., Bingisser R., et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009, 361:858-867.
15. Keller T., Zeller T., Peetz D., Tzikas S., Roth A., Czyz E., Bickel C., Baldus S., Warnholtz A., Fröhlich M., Sinning C.R., Eleftheriadis M.S., Wild P.S., Schnabel R.B., Lubos E., et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009, 361:868-877.
16. Eggers K.M., Lagerqvist B., Venge P., Wallentin L., Lindahl B. Persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome predicts long-term mortality. Circulation 2007, 116:1907-1914.
17. Omland T., de Lemos J.A., Sabatine M.S., Christophi C.A., Rice M.M., Jablonski K.A., Tjora S., Domanski M.J., Gersh B.J., Rouleau J.L., Pfeffer M.A., Braunwald E., Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial Investigators A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009, 361:2538-2547.
18. Lindahl B., Diderholm E., Lagerqvist B., Venge P., Wallentin L., FRISC II (Fast Revascularization during InStability in CAD) Investigators Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol 2001, 38:979-986.
19. Apple F.S., Collinson P.O., IFCC Task Force on Clinical Applications of Cardiac Biomarkers Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012, 58:54-61.
20. Wallace T.W., Abdullah S.M., Drazner M.H., Das S.R., Khera A., McGuire D.K., Wians F., Sabatine M.S., Morrow D.A., de Lemos J.A. Prevalence and determinants of troponin T elevation in the general population. Circulation 2006, 113:1958-1965.
21. Daniels L.B., Laughlin G.A., Clopton P., Maisel A.S., Barrett-Connor E. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. J Am Coll Cardiol 2008, 52:450-459.
22. Otsuka T., Kawada T., Ibuki C., Seino Y. Association between high-sensitivity cardiac troponin T levels and the predicted cardiovascular risk in middle-aged men without overt cardiovascular disease. Am Heart J 2010, 159:972-978.
23. de Lemos J.A., Drazner M.H., Omland T., Ayers C.R., Khera A., Rohatgi A., Hashim I., Berry J.D., Das S.R., Morrow D.A., McGuire D.K. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010, 304:2503-2512.
24. Clerico A., Fortunato A., Ripoli A., Prontera C., Zucchelli G.C., Emdin M. Distribution of plasma cardiac troponin I values in healthy subjects: pathophysiological considerations. Clin Chem Lab Med 2008, 46:804-808.
25. Eggers K.M., Nygren M., Venge P., Jernberg T., Wikström B.G. High-sensitive troponin T and I are related to invasive hemodynamic data and mortality in patients with left-ventricular dysfunction and precapillary pulmonary hypertension. Clin Chim Acta 2011, 412:1582-1588.
26. Apple F.S., Murakami M.M., Pearce L.A., Herzog C.A. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002, 106:2941-2945.
27. Khan N.A., Hemmelgarn B.R., Tonelli M., Thompson C.R., Levin A. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation 2005, 112:3088-3096.
28. Ricchiuti V., Voss E.M., Ney A., Odland M., Anderson P.A., Apple F.S. Cardiac troponin T isoforms expressed in renal diseased skeletal muscle will not cause false-positive results by the second generation cardiac troponin T assay by Boehringer Mannheim. Clin Chem 1998, 44:1919-1924.
29. Jaffe A.S., Vasile V.C., Milone M., Saenger A.K., Olson K.N., Apple F.S. Diseased skeletal muscle: a noncardiac source of increased circulating concentrations of cardiac troponin T. J Am Coll Cardiol 2011, 58:1819-1824.
30. Diris J.H., Hackeng C.M., Kooman J.P., Pinto Y.M., Hermens W.T., van Dieijen-Visser M.P. Impaired renal clearance explains elevated troponin T fragments in hemodialysis patients. Circulation 2004, 109:23-25.
31. Tsutamoto T., Kawahara C., Yamaji M., Nishiyama K., Fujii M., Yamamoto T., Horie M. Relationship between renal function and serum cardiac troponin T in patients with chronic heart failure. Eur J Heart Fail 2009, 11:653-658.
32. Ellis K., Dreisbach A.W., Lertora J.L. Plasma elimination of cardiac troponin I in end-stage renal disease. South Med J 2001, 94:993-996.
33. Vasile V.C., Saenger A.K., Kroning J.M., Jaffe A.S. Biological and analytical variability of a novel high-sensitivity cardiac troponin T assay. Clin Chem 2010, 56:1086-1090.
34. Wu A.H., Lu Q.A., Todd J., Moecks J., Wians F. Short- and long-term biological variation in cardiac troponin I measured with a high-sensitivity assay: implications for clinical practice. Clin Chem 2009, 55:52-58.
35. Feng J., Schaus B.J., Fallavollita J.A., Lee T.C., Canty J.M. Preload induces troponin I degradation independently of myocardial ischemia. Circulation 2001, 103:2035-2037.
36. Mann D.L., Kent R.L., Parsons B., Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992, 85:790-804.
37. Tan L.B., Jalil J.E., Pick R., Janicki J.S., Weber K.T. Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991, 69:1185-1195.
38. Kajstura J., Cigola E., Malhotra A., Li P., Cheng W., Meggs L.G., Anversa P. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 1997, 29:859-870.
39. Krown K.A., Page M.T., Nguyen C., Zechner D., Gutierrez V., Comstock K.L., Glembotski C.C., Quintana P.J., Sabbadini R.A. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996, 98:2854-2865.
40. Teiger E., Than V.D., Richard L., Wisnewsky C., Tea B.S., Gaboury L., Tremblay J., Schwartz K., Hamet P. Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest 1996, 97:2891-2897.
41. Hessel M.H., Atsma D.E., van der Valk E.J., Bax W.H., Schalij M.J., van der Laarse A. Release of cardiac troponin I from viable cardiomyocytes is mediated by integrin stimulation. Pflugers Arch 2008, 455:979-986.
42. Mann D.L., Bristow M.R. Mechanisms and models in heart failure. The biochemical model and beyond. Circulation 2005, 111:2837-2849.
43. Horwich T.B., Patel J., MacLellan W.R., Fonarow G.C. Cardiac troponin I is associated with impaired hemodynamics, progressive LV dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003, 108:833-838.
44. Nishio Y., Sato Y., Taniguchi R., Shizuta S., Doi T., Morimoto T., Kimura T., Kita T. Cardiac troponin T vs other biochemical markers in patients with congestive heart failure. Circ J 2007, 71:631-635.
45. Latini R., Masson S., Anand I.S., Missov E., Carlson M., Vago T., Angelici L., Barlera S., Parrinello G., Maggioni A.P., Tognoni G., Cohn J.N., Val-HeFT Investigators Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007, 116:1242-1249.
46. Kuwabara Y., Sato Y., Miyamoto T., Taniguchi R., Matsuoka T., Isoda K., Yamane K., Nishi K., Fujiwara H., Takatsu Y. Persistently increased serum concentrations of cardiac troponin in patients with acutely decompensated heart failure are predictive of adverse outcomes. Circ J 2007, 71:1047-1051.
47. Peacock W.F., De Marco T., Fonarow G.C., Diercks D., Wynne J., Apple F.S., Wu A.H., ADHERE Investigators Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008, 358:2117-2126.
48. Sato Y., Kuwabara Y., Taniguchi R., Nishio Y., Miyamoto T., Fujiwara H., Takatsu Y. Malignant link between chronic heart failure and acute cardiac decompensation in patients with persistently increased serum concentrations of cardiac troponin. Int J Cardiol 2008, 126:171-176.
49. Gheorghiade M., Zannad F., Sopko G., Klein L., Piña I.L., Konstam M.A., Massie B.M., Roland E., Targum S., Collins S.P., Filippatos G., Tavazzi L., International Working Group on Acute Heart Failure Syndromes Acute heart failure syndromes: current state and framework for future research. Circulation 2005, 112:3958-3968.
50. de Lemos J.A., McGuire D.K., Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 2003, 362:316-322.
51. Sato Y., Nishi K., Saijo S., Tanada Y., Goto T., Takahashi N., Yamamoto E., Fukuhara R., Miyamoto T., Taniguchi R., Fujiwara H., Takatsu Y. Serial measurements of high sensitive cardiac troponin I in patients with acutely decompensated heart failure treated with carperitide or nitrates. J Cardiol 2010, 56:66-72.
52. Miller W.L., Hartman K.A., Burritt M.F., Borgeson D.D., Burnett J.C., Jaffe A.S. Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure. Clin Chem 2005, 51:569-577.
53. Missov E., Calzolari C., Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997, 96:2953-2958.
54. Sato Y., Kataoka K., Matsumori A., Sasayama S., Yamada T., Ito H., Takatsu Y. Measuring serum aminoterminal type III procollagen peptide, 7S domain of type IV collagen, and cardiac troponin T in patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathy. Heart 1997, 78:505-508.
55. Sato Y., Yamada T., Taniguchi R., Nagai K., Makiyama T., Okada H., Kataoka K., Ito H., Matsumori A., Sasayama S., Takatsu Y. Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001, 103:369-374.
56. Ishii J., Cui W., Kitagawa F., Kuno T., Nakamura Y., Naruse H., Mori Y., Ishikawa T., Nagamura Y., Kondo T., Oshima H., Nomura M., Ezaki K., Hishida H. Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure. Clin Chem 2003, 49:2020-2026.
57. Taniguchi R., Sato Y., Yamada T., Ooba M., Higuchi H., Matsumori A., Kimura T., Kita T. Combined measurements of cardiac troponin T and N-terminal pro-brain natriuretic peptide in patients with heart failure. Circ J 2004, 68:1160-1164.
58. Perna E.R., Macin S.M., Canella J.P., Augier N., Stival J.L., Cialzeta J.R., Pitzus A.E., Garcia E.H., Obregón R., Brizuela M., Barbagelata A. Ongoing myocardial injury in stable severe heart failure. Value of cardiac troponin T monitoring for high-risk patient identification. Circulation 2004, 110:2376-2382.
59. Taniguchi R., Sato Y., Nishio Y., Kimura T., Kita T. Measurements of baseline and follow-up concentrations of cardiac troponin-T and brain natriuretic peptide in patients with heart failure from various etiologies. Heart Vessels 2006, 21:344-349.
60. Sato Y., Kita T., Takatsu Y., Kimura T. Biochemical markers of myocyte injury in heart failure. Heart 2004, 90:1110-1113.
61. Sato Y., Taniguchi R., Makiyama T., Nagai K., Okada H., Yamada T., Matsumori A., Takatsu Y. Serum cardiac troponin T and plasma brain natriuretic peptide in patients with cardiac decompensation. Heart 2002, 88:647-648.
62. Gheorghiade M., Gattis Stough W., Adams K.F., Jaffe A.S., Hasselblad V., O'Connor C.M. The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF). Am J Cardiol 2005, 96:18G-25G.
63. Sakhuja R., Green S., Oestreicher E.M., Sluss P.M., Lee-Lewandrowski E., Lewandrowski K.B., Januzzi J.L. Amino-terminal pro-brain natriuretic peptide, brain natriuretic peptide, and troponin T for prediction of mortality in acute heart failure. Clin Chem 2007, 53:412-420.
64. Metra M., Nodari S., Parrinello G., Specchia C., Brentana L., Rocca P., Fracassi F., Bordonali T., Milani P., Danesi R., Verzura G., Chiari E., Dei Cas L. The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. Eur J Heart Fail 2007, 9:776-786.
65. Fonarow G.C., Peacock W.F., Horwich T.B., Phillips C.O., Givertz M.M., Lopatin M., Wynne J., ADHERE Scientific Advisory Committee and Investigators Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. Am J Cardiol 2008, 101:231-237.
66. Masson S., Anand I., Favero C., Barlera S., Vago T., Bertocchi F., Maggioni A.P., Tavazzi L., Tognoni G., Cohn J.N., Latini R., Valsartan Heart Failure Trial (Val-HeFT) and Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Investigators Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from two large randomized clinical trials. Circulation 2012, 125:280-288.
67. Miller W.L., Hartman K.A., Burritt M.F., Grill D.E., Rodeheffer R.J., Burnett J.C., Jaffe A.S. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation 2007, 116:249-257.
68. Miller W.L., Hartman K.A., Burritt M.F., Grill D.E., Jaffe A.S. Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. J Am Coll Cardiol 2009, 54:1715-1721.
69. Biolo A., Fisch M., Balog J., Chao T., Schulze P.C., Ooi H., Siwik D., Colucci W.S. Episodes of acute heart failure syndrome are associated with increased levels of troponin and extracellular matrix markers. Circ Heart Fail 2010, 3:44-50.
70. Xue Y., Clopton P., Peacock W.F., Maisel A.S. Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure. Eur J Heart Fail 2011, 13:37-42.
71. Sato Y., Nishi K., Taniguchi R., Miyamoto T., Fukuhara R., Yamane K., Saijo S., Tanada Y., Yamamoto E., Goto T., Takahashi N., Fujiwara H., Takatsu Y. In patients with heart failure and non-ischemic heart disease, cardiac troponin T is a reliable predictor of long-term echocardiographic changes and adverse cardiac events. J Cardiol 2009, 54:221-230.
72. Aarones M., Gullestad L., Aakhus S., Ueland T., Skaardal R., Aass H., Wergeland R., Smith H.J., Aukrust P., Kongsgaard E. Prognostic value of cardiac troponin T in patients with moderate to severe heart failure scheduled for cardiac resynchronization therapy. Am Heart J 2011, 161:1031-1037.
73. Fertin M., Hennache B., Hamon M., Ennezat P.V., Biausque F., Elkohen M., Nugue O., Tricot O., Lamblin N., Pinet F., Bauters C. Usefulness of serial assessment of B-type natriuretic peptide, troponin I, and C-reactive protein to predict left ventricular remodeling after acute myocardial infarction (from the REVE-2 study). Am J Cardiol 2010, 106:1410-1416.
74. Sato Y., Yamamoto E., Sawa T., Toda K., Hara T., Iwasaki T., Fujiwara H., Takatsu Y. High-sensitivity cardiac troponin T in essential hypertension. J Cardiol 2011, 58:226-231.
75. Zethelius B., Johnston N., Venge P. Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: a community-based cohort study. Circulation 2006, 113:1071-1078.
76. Sundström J., Ingelsson E., Berglund L., Zethelius B., Lind L., Venge P., Arnlöv J. Cardiac troponin-I and risk of heart failure: a community-based cohort study. Eur Heart J 2009, 30:773-781.
77. Saunders J.T., Nambi V., de Lemos J.A., Chambless L.E., Virani S.S., Boerwinkle E., Hoogeveen R.C., Liu X., Astor B.C., Mosley T.H., Folsom A.R., Heiss G., Coresh J., Ballantyne C.M. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation 2011, 123:1367-1376.
78. deFilippi C.R., de Lemos J.A., Christenson R.H., Gottdiener J.S., Kop W.J., Zhan M., Seliger S.L. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010, 304:2494-2502.
79. Sato Y., Taniguchi R., Nagai K., Makiyama T., Okada H., Yamada T., Matsumori A., Takatsu Y. Measurements of cardiac troponin T in patients with hypertrophic cardiomyopathy. Heart 2003, 89:659-660.
80. Moreno V., Hernández-Romero D., Vilchez J.A., García-Honrubia A., Cambronero F., Casas T., González J., Martínez P., Climent V., de la Morena G., Valdés M., Marín F. Serum levels of high-sensitivity troponin T: a novel marker for cardiac remodeling in hypertrophic cardiomyopathy. J Card Fail 2010, 16:950-956.
81. Kubo T., Kitaoka H., Okawa M., Yamanaka S., Hirota T., Hoshikawa E., Hayato K., Yamasaki N., Matsumura Y., Yasuda N., Sugiura T., Doi Y.L. Serum cardiac troponin I is related to increased left ventricular wall thickness, left ventricular dysfunction, and male gender in hypertrophic cardiomyopathy. Clin Cardiol 2010, 33:E1-E7.
82. Kubo T., Kitaoka H., Okawa M., Yamanaka S., Hirota T., Baba Y., Hayato K., Yamasaki N., Matsumura Y., Yasuda N., Sugiura T., Doi Y.L. Combined measurements of cardiac troponin I and brain natriuretic peptide are useful for predicting adverse outcomes in hypertrophic cardiomyopathy. Circ J 2011, 75:919-926.
83. Cambronero F., Marín F., Roldán V., Hernández-Romero D., Valdés M., Lip G.Y. Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. Eur Heart J 2009, 30:139-151.
84. Cooper L.T. Myocarditis. N Engl J Med 2009, 360:1526-1538.
85. Lauer B., Niederau C., Kühl U., Schannwell M., Pauschinger M., Strauer B.E., Schultheiss H.P. Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol 1997, 30:1354-1359.
86. Smith S.C., Ladenson J.H., Mason J.W., Jaffe A.S. Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. Circulation 1997, 95:163-168.
87. Kadota S., Takeuchi Y., Izuhara M., Baba O., Shioji K., Uegaito T., Kadota E., Matsuda M. The importance of serial cardiac troponin measurement for evaluating the response to immunosuppressive therapy for myocarditis. J Cardiol 2008, 52:154-158.
88. Sato Y., Taniguchi R., Yamada T., Nagai K., Makiyama T., Okada H., Matsumori A., Sasayama S., Takatsu Y. Measurement of serum concentrations of cardiac troponin T in patients with hypereosinophilic syndrome: a sensitive non-invasive marker of cardiac disorder. Intern Med 2000, 39:350.
89. Sato Y., Takatsu Y., Yamada T., Kataoka K., Taniguchi R., Mimura R., Sasayama S., Matsumori A. Interferon treatment for dilated cardiomyopathy and striated myopathy associated with hepatitis C virus infection based on serial measurements of serum concentrations of cardiac troponin T. Jpn Circ J 2000, 64:321-324.
90. Dispenzieri A., Kyle R.A., Gertz M.A., Therneau T.M., Miller W.L., Chandrasekaran K., McConnell J.P., Burritt M.F., Jaffe A.S. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003, 361:1787-1789.
91. Kristen A.V., Giannitsis E., Lehrke S., Hegenbart U., Konstandin M., Lindenmaier D., Merkle C., Hardt S., Schnabel P.A., Röcken C., Schonland S.O., Ho A.D., Dengler T.J., Katus H.A. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood 2010, 116:2455-2461.
92. Kato T., Sato Y., Nagao K., Horie T., Kataoka K., Miyamoto T., Takatsu Y. Serum cardiac troponin T in cardiac amyloidosis: serial observations in five patients. Tohoku J Exp Med 2006, 208:163-167.
93. Palladini G., Barassi A., Klersy C., Pacciolla R., Milani P., Sarais G., Perlini S., Albertini R., Russo P., Foli A., Bragotti L.Z., Obici L., Moratti R., Melzi d'Eril G.V., Merlini G. The combination of high-sensitivity cardiac troponin T (Hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 2010, 116:3426-3430.
94. Cardinale D., Sandri M.T., Martinoni A., Tricca A., Civelli M., Lamantia G., Cinieri S., Martinelli G., Cipolla C.M., Fiorentini C. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000, 36:517-522.
95. Cardinale D., Sandri M.T., Colombo A., Colombo N., Boeri M., Lamantia G., Civelli M., Peccatori F., Martinelli G., Fiorentini C., Cipolla C.M. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004, 109:2749-2754.
96. Germanakis I., Anagnostatou N., Kalmanti M. Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity. Pediatr Blood Cancer 2008, 51:327-333.
97. Dolci A., Dominici R., Cardinale D., Sandri M.T., Panteghini M. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol 2008, 130:688-695.
98. Sawaya H., Sebag I.A., Plana J.C., Januzzi J.L., Ky B., Cohen V., Gosavi S., Carver J.R., Wiegers S.E., Martin R.P., Picard M.H., Gerszten R.E., Halpern E.F., Passeri J., Kuter I., et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 2011, 107:1375-1380.
99. O'Brien P.J. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology 2008, 245:206-218.
100. Apple F.S., Murakami M.M., Ler R., Walker D., York M., HESI Technical Committee of Biomarkers Working Group on Cardiac Troponins Analytical characteristics of commercial cardiac troponin I and T immunoassays in serum from rats, dogs, and monkeys with induced acute myocardial injury. Clin Chem 2008, 54:1982-1989.